News & Updates
Filter by Specialty:
BNT162b2 booster protects against COVID-19 infection, hospitalization in adolescents
In a national cohort study in Singapore, a booster dose of BNT162b2 maintained individual protection against severe COVID-19 disease among adolescents aged 12–17 years.
BNT162b2 booster protects against COVID-19 infection, hospitalization in adolescents
13 Jun 2023
Post-treatment HBsAg loss greater with TDF vs entecavir
In patients with chronic hepatitis B (CHB) without cirrhosis, the rates of hepatitis B surface antigen (HBsAg) loss appear to be higher after discontinuation of tenofovir disoproxil fumarate (TDF) than of entecavir, and this is particularly true for patients who have not experienced relapse after treatment discontinuation, according to a study.
Post-treatment HBsAg loss greater with TDF vs entecavir
12 Jun 2023
Progression-free on immunotherapy for NSCLC? Stopping treatment at 2 years may be OK
For patients with advanced nonsmall cell lung cancer (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.